目的 探討參一膠囊聯(lián)合羥基喜樹堿氯化鈉注射液和順鉑注射液治療晚期非小細胞肺癌的臨床研究。方法 選擇2017年6月-2018年6月渭南市中心醫(yī)院收治的68例非小細胞肺癌患者為研究對象，依據(jù)隨機數(shù)表法將所有患者隨機分為對照組和治療組，每組各34例。對照組患者靜脈滴注順鉑注射液，75 mg/d，1次/3周；第1~5天靜脈滴注羥基喜樹堿氯化鈉注射液，10 mg/d；治療組患者在對照組治療的基礎(chǔ)上口服參一膠囊，2粒/次，2次/d。3周為1個周期，兩組患者均治療2個周期。觀察兩組的臨床療效，比較兩組的生活質(zhì)量、免疫指標和不良反應。結(jié)果 治療后，對照組和治療組的臨床總緩解率（RR）分別為32.35%、55.88%，疾病控制率（DCR）分別為67.65%、85.29%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，對照組和治療組的生活質(zhì)量提高率分別為47.06%、67.65%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺均明顯升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療后治療組患者免疫指標均明顯高于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組血細胞降低、惡心嘔吐發(fā)生情況明顯低于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。結(jié)論 參一膠囊聯(lián)合羥基喜樹堿氯化鈉注射液和順鉑注射液治療晚期非小細胞肺癌的臨床效果較好，可提高患者生活質(zhì)量，調(diào)節(jié)免疫功能，安全性較好，具有一定的臨床推廣應用價值。

Objective To investigate the effects of Shenyi Capsules combined with Hydroxycamptothecin and Sodium Chloride Injection and Cisplatin Injection in treatment of advanced non-small cell lung cancer. Methods Patients (68 cases) with advanced non-small cell lung cancer in Weinan Central Hospital from June 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were iv administered with Cisplatin Injection, 75 mg/d, once every 3 weeks. And at the first to fifth day, patients in the control group were also iv administered with Hydroxycamptothecin and Sodium Chloride Injection, 10 mg/d. Patients in the treatment group were po administered with Shenyi Capsules on the basis of the control group, 2 grains/time, twice daily. A cycle had 3 weeks, and patients in two groups were treated for 2 cycles. After treatment, the clinical efficacies were evaluated, and quality of life, immune indexes, and adverse reactions in two groups were compared. Results After treatment, the RR in the control and treatment groups were 32.35% and 55.88%, respectively, and the DCR in the control and treatment groups were 67.65% and 85.29%, respectively, and there was difference between two groups (P<0.05). After treatment, the improvement rates of quality of life in the control and treatment groups were 47.06% and 67.65%, respectively, and there was difference between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the immune indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the occurrence situation of hemocytopenia and nausea and vomiting in the treatment group were significantly lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Shenyi Capsules combined with Hydroxycamptothecin and Sodium Chloride Injection and Cisplatin Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life, and regulate the immune function, with good safety, which has a certain clinical application value.

R979.1